Tempest Therapeutics, Inc.
TPST- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001544227
No open-market purchases or sales by Tempest Therapeutics, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q3 2026, worth $682.2K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:24 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Mar 27, 2025 | Mar 19, 2024 | Mar 22, 2023 | Mar 29, 2022 |
| Research and development | $12.6M | $28.5M | $17.5M | $22.5M | $17.2M |
| Selling, general and administrative | $14.0M | $13.6M | $11.7M | $12.1M | $9.82M |
| Operating income | -$26.6M | -$42.0M | -$29.2M | -$34.6M | -$27.0M |
| Interest expense | – | – | $1.45M | $1.62M | $1.28M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$26.3M | -$41.8M | -$29.5M | -$35.7M | -$28.3M |
| EPS, basic | $-6.33 | $-1.50 | $-1.91 | $-3.09 | $-7.47 |
| EPS, diluted | $-6.33 | $-1.50 | $-1.91 | $-3.09 | $-7.47 |
| Weighted shares, basic | 4.15M | 27.9M | 15.4M | 11.5M | 3.79M |
| Weighted shares, diluted | 4.15M | 27.9M | 15.4M | 11.5M | 3.79M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Mar 27, 2025 | Mar 19, 2024 | Mar 22, 2023 | Mar 29, 2022 |
| Cash and equivalents | $7.71M | $30.3M | $39.2M | $31.2M | $51.8M |
| Total current assets | $8.27M | $31.5M | $40.4M | $33.0M | $69.0M |
| Property, plant and equipment | $605.0K | $886.0K | $840.0K | $1.06M | $1.11M |
| Total assets | $16.9M | $41.5M | $51.6M | $46.1M | $73.2M |
| Accounts payable | $1.04M | $2.45M | $845.0K | $1.11M | $991.0K |
| Short-term debt | $0 | $6.35M | $4.29M | – | – |
| Total current liabilities | $3.31M | $14.2M | $9.41M | $7.28M | $20.0M |
| Long-term debt | – | $0 | $6.26M | $10.4M | $15.1M |
| Total liabilities | $10.3M | $22.4M | $24.8M | $28.0M | $37.1M |
| Shareholders' equity | $6.67M | $19.1M | $26.8M | $18.1M | $36.1M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 30, 2026 | Mar 27, 2025 | Mar 19, 2024 | Mar 22, 2023 | Mar 29, 2022 |
| Operating cash flow | -$26.8M | -$33.0M | -$27.4M | -$31.1M | -$26.0M |
| Capital expenditures | $0 | $435.0K | $170.0K | $562.0K | $135.0K |
| Free cash flow | -$26.8M | -$33.5M | -$27.5M | -$31.6M | -$26.1M |
| Stock-based compensation | $3.12M | $5.30M | $2.55M | $1.56M | $1.10M |
| Investing cash flow | $0 | -$435.0K | -$170.0K | -$562.0K | -$97.0K |
| Financing cash flow | $4.26M | $24.5M | $35.6M | $11.4M | $59.1M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 13, 2026 | 20.0M | +350.3% | SEC |
| May 8, 2026 | 14.8M | +302.1% | SEC |
| Mar 25, 2026 | 14.3M | −68.5% | SEC |
| Oct 30, 2025 | 4.44M | −89.8% | SEC |
| Aug 4, 2025 | 4.44M | −82.4% | SEC |
| May 8, 2025 | 3.68M | −83.4% | SEC |
| Apr 25, 2025 | 3.66M | −83.5% | SEC |
| Mar 21, 2025 | 45.5M | +105.0% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-13 in Q2 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.